A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

The mammalian target of rapamycin (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is attenuated by feedback up-regulation of AKT mediated in part by Insulin-like growth factor...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Breast Cancer Res Treat
Prif Awduron: Ma, Cynthia X., Suman, Vera J., Goetz, Matthew, Haluska, Paul, Moynihan, Timothy, Nanda, Rita, Olopade, Olufunmilayo, Pluard, Timothy, Guo, Zhanfang, Chen, Helen X., Erlichman, Charles, Ellis, Matthew J., Fleming, Gini F.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2013
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4517667/
https://ncbi.nlm.nih.gov/pubmed/23605083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2528-8
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg